Evidence map›Paper›PMID 26604259›Full record

ArticlemBio2015

Phylogenetic Distribution of CRISPR-Cas Systems in Antibiotic-Resistant Pseudomonas aeruginosa.

Alex van Belkum, Leah B Soriaga, Matthew C LaFave, Srividya Akella, Jean-Baptiste Veyrieras, E Magda Barbu, Dee Shortridge, Bernadette Blanc, Gregory Hannum, Gilles Zambardi and 11 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 234 citations in OpenAlex.

  1. Review
  2. The H-NS homologues MvaT and MvaU repress CRISPR-Cas inPhilosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025
    Article
  3. Comparative genomics ofJournal of bacteriology · 2025
    Article
  4. Review
  5. Detection of the ST111 Global High-RiskCurrent issues in molecular biology · 2025
    Article
  6. Bacteriophages inMicrobial genomics · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025
    Review
  11. Article
  12. AvirulentmicroLife · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 3 countries.

Alex van BelkumbioMérieux, Marcy l'Etoile, France.
Leah B SoriagaSynthetic Genomics, Inc., La Jolla, California, USA.
Matthew C LaFaveSynthetic Genomics, Inc., La Jolla, California, USA.
Srividya AkellaSynthetic Genomics, Inc., La Jolla, California, USA.
Jean-Baptiste VeyrierasbioMérieux, Marcy l'Etoile, France.
E Magda BarbuSynthetic Genomics, Inc., La Jolla, California, USA.
Dee ShortridgebioMérieux, Marcy l'Etoile, France.
Bernadette BlancbioMérieux, Marcy l'Etoile, France.
Gregory HannumSynthetic Genomics, Inc., La Jolla, California, USA.
Gilles ZambardibioMérieux, Marcy l'Etoile, France.
Kristofer MillerSynthetic Genomics, Inc., La Jolla, California, USA.
Mark C EnrightManchester Metropolitan University, Manchester, United Kingdom.
Nathalie MugnierbioMérieux, Marcy l'Etoile, France.
Daniel BramiSynthetic Genomics, Inc., La Jolla, California, USA.
Stéphane SchicklinbioMérieux, Marcy l'Etoile, France.
Martina FeldermanSynthetic Genomics, Inc., La Jolla, California, USA.
Ariel S SchwartzSynthetic Genomics, Inc., La Jolla, California, USA.
Toby H RichardsonSynthetic Genomics, Inc., La Jolla, California, USA.
Todd C PetersonSynthetic Genomics, Inc., La Jolla, California, USA.
Bolyn HubbySynthetic Genomics, Inc., La Jolla, California, USA.
Kyle C CadySynthetic Genomics, Inc., La Jolla, California, USA kcady@syntheticgenomics.com.
Synthetic Genomics (United States) · USbioMérieux (France) · FRManchester Metropolitan University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledPseudomonas aeruginosa is an antibiotic-refractory pathogen with a large genome and extensive genotypic diversity. Historically, P. aeruginosa has been a major model system for understanding the molecular mechanisms underlying type I clustered regularly interspaced short palindromic repeat (CRISPR) and CRISPR-associated protein (CRISPR-Cas)-based bacterial immune system function. However, little information on the phylogenetic distribution and potential role of these CRISPR-Cas systems in molding the P. aeruginosa accessory genome and antibiotic resistance elements is known. Computational approaches were used to identify and characterize CRISPR-Cas systems within 672 genomes, and in the process, we identified a previously unreported and putatively mobile type I-C P. aeruginosa CRISPR-Cas system. Furthermore, genomes harboring noninhibited type I-F and I-E CRISPR-Cas systems were on average ~300 kb smaller than those without a CRISPR-Cas system. In silico analysis demonstrated that the accessory genome (n = 22,036 genes) harbored the majority of identified CRISPR-Cas targets. We also assembled a global spacer library that aided the identification of difficult-to-characterize mobile genetic elements within next-generation sequencing (NGS) data and allowed CRISPR typing of a majority of P. aeruginosa strains. In summary, our analysis demonstrated that CRISPR-Cas systems play an important role in shaping the accessory genomes of globally distributed P. aeruginosa isolates. IMPORTANCE: P. aeruginosa is both an antibiotic-refractory pathogen and an important model system for type I CRISPR-Cas bacterial immune systems. By combining the genome sequences of 672 newly and previously sequenced genomes, we were able to provide a global view of the phylogenetic distribution, conservation, and potential targets of these systems. This analysis identified a new and putatively mobile P. aeruginosa CRISPR-Cas subtype, characterized the diverse distribution of known CRISPR-inhibiting genes, and provided a potential new use for CRISPR spacer libraries in accessory genome analysis. Our data demonstrated the importance of CRISPR-Cas systems in modulating the accessory genomes of globally distributed strains while also providing substantial data for subsequent genomic and experimental studies in multiple fields. Understanding why certain genotypes of P. aeruginosa are clinically prevalent and adept at horizontally acquiring virulence and antibiotic resistance elements is of major clinical and economic importance.

Indexed as

CRISPR-Cas SystemsDrug Resistance, BacterialGenetic VariationPhylogenyAnti-Bacterial AgentsComputational BiologyGenome, BacterialPseudomonas aeruginosaSequence Analysis, DNAAnti-Bacterial Agents

Identifiers

PMID26604259
PMCPMC4669384
OpenAlexW2174616186

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.